Accessibility Menu
Sagimet Biosciences logo

Sagimet Biosciences(NASDAQ) SGMT

Current Price$7.06
Market Cap$436.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-56%
5 YearN/A
1 Year-31%
1 Month+2%
Sagimet Biosciences last closing stock price
MetricPriceDate
Last closeUSD 7.072026-07-24
Sagimet Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.59%USD 7.822026-07-17
1 month+2.02%USD 6.932026-06-24
3 month+20.65%USD 5.862026-04-24
Year to date+19.43%USD 5.922025-12-31
1 year-30.69%USD 10.202025-07-24
3 year-55.87%USD 16.022023-07-25
Since inception-55.67%USD 15.952023-07-14

Sagimet Biosciences Financials at a Glance

Market Cap

$436.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$43.51M

EPS (TTM)

-$1.34

P/E Ratio

-5.27

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$7.06

Volume

910,937.025

Open

$7.14

Previous Close

$7.07

Daily Range

$6.86 - $7.20

52-Week Range

$4.50 - $10.46

Estimated Earnings Date

Aug 12, 2026

SGMT News

biopharma research and testing

Why Sagimet Biosciences Stock Is Soaring Today

James BrumleyApr 27, 2026
Foolcom-Featured.png

Sagimet Biosciences Tops Q2 EPS Forecast

Motley Fool Markets TeamAug 13, 2025

SGMT: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sagimet Biosciences

Sagimet creates oral pills to treat liver disease and skin conditions. These pills help people with too much fat in their organs. The company focuses on fixing metabolic problems that lead to scarring.

What Is Sagimet Making?

  • Denifanstat for MASH: Oral once-daily pill targeting liver fat, inflammation, and scarring in patients with metabolic liver disease.
  • TVB-3567 for Acne: Small molecule designed to reduce skin oil production for treating moderate to severe acne.
  • Denifanstat for Acne: Medicine currently under regulatory review in China to treat skin lesions and inflammation.
  • Oncology Research: Experimental treatments for specific solid tumors that depend on fatty acid pathways for growth.

Growth and Clinical Milestones

  • Maintains a licensing agreement with Ascletis BioScience to develop and sell denifanstat in Greater China.
  • Received FDA Breakthrough Therapy designation for denifanstat to treat liver disease in October 2024.
  • Ascletis submitted a New Drug Application in China for acne treatment in December 2025.
  • Completed a Phase 1 trial for a combination of denifanstat and resmetirom in December 2025.
  • Launched a first-in-human Phase 1 clinical trial for TVB-3567 in June 2025.

How Sagimet Stands Out

The company uses a precision medicine strategy. It uses biomarkers, which are biological markers in the blood, to find patients who will respond best.

The Financial Scorecard

  • Operating loss was $10.8 million in Q4 2025, which improved 40.8% from the $18.2 million loss in Q4 2024.
  • Net loss reached $9.6 million in Q4 2025, narrowing by 40.9% year-over-year.
  • Free cash flow was negative $11.8 million in Q4 2025, a 7.3% deeper deficit compared to Q4 2024.
  • Market capitalization grew to $191.5 million in Q4 2025, up 32.2% from the previous year.

Bottom Line

Sagimet has transitioned from early research to late-stage clinical testing for liver and skin diseases. Its focus on fat-blocking drugs allows it to address multiple large health markets.

AI Generated • May 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

David A. Happel, MBA

Website

www.sagimet.com

Headquarters

San Mateo, CA 94402, US

SGMT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-37.57%

Return on Capital

-51.04%

Return on Assets

-40.38%

Earnings Yield

-18.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$436.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

61.75M

Volume

910.94K

Avg. Volume

1.96M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$48.74M

EBITDA

-$46.14M

Operating Cash Flow

-$39.73M

Capital Expenditure

$0.00

Free Cash Flow

-$39.73M

Cash & ST Invst.

$104.54M

Total Debt

$39.00K

Sagimet Biosciences Performance Analysis

Sagimet Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 2,000,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Sagimet Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Sagimet Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.4324.8%
20232023-12-31USD -1.22-14.7%
20242024-12-31USD -1.4519.4%
20252025-12-31USD -1.588.6%
Sagimet Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3042.9%
Q32025-09-30-25.0%
Q42025-12-3125.0%
Q12026-03-31-10.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$436.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$27.29M

N/A

Employees

16

N/A

Net Income

-$10.65M

+41.4%

EBITDA

-$10.65M

+41.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$104.54M

-27.7%

Total Debt

$39.00K

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$39.00K

+0.0%

Return on Assets

-40.38%

N/A

Return on Invested Capital

-47.57%

N/A

Free Cash Flow

-$8.61M

+40.8%

Operating Cash Flow

-$8.61M

+40.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ASMBAssembly Biosciences, Inc.
$25.55+1.31%
AVIRAtea Pharmaceuticals, Inc.
$4.73-0.42%
ZURAZura Bio Limited
$5.23-1.13%
FHTXFoghorn Therapeutics Inc.
$4.85-4.34%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%

Questions About SGMT

What is the current price of Sagimet Biosciences?

Sagimet Biosciences is trading at $7.07 per share.

What is the 52-week range for Sagimet Biosciences?

Over the past 52 weeks, Sagimet Biosciences has traded between $4.50 and $10.46.

How much debt does Sagimet Biosciences have?

As of the most recent reporting period, Sagimet Biosciences reported total debt of $39.00K.

How much cash does Sagimet Biosciences have on hand?

Sagimet Biosciences reported $36.63M in cash and cash equivalents in its most recent financial results.

What is Sagimet Biosciences’s dividend yield?

Sagimet Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services